{"schema_version":"secwatch.filing_event.v1","accession":"0001193805-23-001493","form_type":"8-K","ticker":"ARCT","cik":"0001768224","company_name":"Arcturus Therapeutics Holdings Inc.","filed_at":"2023-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.362042+00:00","generated_at":"2026-06-08T03:53:27.666508+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Arcturus Q3 revenue $45.1M, net loss narrowed; cash runway extended to 2026; ARCT-154 on track for Japan approval","bullets":["Revenue of $45.1M for Q3 2023 ($13.4M in Q3 2022); net loss $16.2M ($0.61/share) improved from $35.3M loss.","Cash, equivalents and restricted cash $369.1M; expected runway extended to end of 2026.","$35M milestone achieved from CSL Seqirus; total milestones received $365M to date.","ARCT-154 monovalent COVID vaccine on track for Japan NDA approval in December; Phase 3 bivalent trial enrollment target (850 participants) reached.","ARCT-032 Phase 1b initiated; first CF patient dosing this month; FDA Rare Pediatric Disease Designation granted."],"urls":{"canonical":"https://secwatch.observer/filing/0001193805-23-001493","json":"https://secwatch.observer/filing/0001193805-23-001493.json","markdown":"https://secwatch.observer/filing/0001193805-23-001493.md","text":"https://secwatch.observer/filing/0001193805-23-001493.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1768224/000119380523001493/0001193805-23-001493-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1768224/000119380523001493/e619057_8k-arct.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T03:53:27.666508+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f51965dfc8968538f27748d30ce750fc0cacea6b","claim":"Arcturus Therapeutics Holdings Inc. reported financial results for third quarter ended Sept. 30, 2023.","evidence_excerpt":"On November 14, 2023, Arcturus Therapeutics Holdings Inc. (the “Company” or “Arcturus”) issued a press release, a copy of which is furnished herewith as Exhibit 99.1, announcing the Company’s financial results for the quarter ended September 30, 2023 and providing a corporate update (the “Press Release”).","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1768224/000119380523001493/0001193805-23-001493-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended Sept. 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}